CN104411678A - 用于治疗糖尿病性视网膜病及其他眼科疾病的方法 - Google Patents

用于治疗糖尿病性视网膜病及其他眼科疾病的方法 Download PDF

Info

Publication number
CN104411678A
CN104411678A CN201380035735.1A CN201380035735A CN104411678A CN 104411678 A CN104411678 A CN 104411678A CN 201380035735 A CN201380035735 A CN 201380035735A CN 104411678 A CN104411678 A CN 104411678A
Authority
CN
China
Prior art keywords
substituted
patient
compound
unsubstituted
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380035735.1A
Other languages
English (en)
Chinese (zh)
Inventor
克拉斯·奥洛夫·贝文
苏珊·海斯·亨利
辽·洼田
弗拉基米拉·A·库克萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kubota Vision Inc
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Priority to CN201710706410.1A priority Critical patent/CN107865830A/zh
Priority to CN202310810454.4A priority patent/CN116850163A/zh
Publication of CN104411678A publication Critical patent/CN104411678A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201380035735.1A 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法 Pending CN104411678A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710706410.1A CN107865830A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法
CN202310810454.4A CN116850163A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261643178P 2012-05-04 2012-05-04
US201261643058P 2012-05-04 2012-05-04
US201261643051P 2012-05-04 2012-05-04
US61/643,051 2012-05-04
US61/643,178 2012-05-04
US61/643,058 2012-05-04
US201361781907P 2013-03-14 2013-03-14
US61/781,907 2013-03-14
PCT/US2013/039562 WO2013166449A2 (en) 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202310810454.4A Division CN116850163A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法
CN201710706410.1A Division CN107865830A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法

Publications (1)

Publication Number Publication Date
CN104411678A true CN104411678A (zh) 2015-03-11

Family

ID=49515046

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380035735.1A Pending CN104411678A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法
CN201710706410.1A Pending CN107865830A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法
CN202310810454.4A Pending CN116850163A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710706410.1A Pending CN107865830A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法
CN202310810454.4A Pending CN116850163A (zh) 2012-05-04 2013-05-03 用于治疗糖尿病性视网膜病及其他眼科疾病的方法

Country Status (18)

Country Link
US (4) US9957224B2 (enExample)
EP (2) EP2844636B1 (enExample)
JP (6) JP2015518491A (enExample)
KR (1) KR20150013240A (enExample)
CN (3) CN104411678A (enExample)
AU (1) AU2013256029A1 (enExample)
BR (1) BR112014027571B1 (enExample)
CA (1) CA2872433C (enExample)
EA (1) EA201492031A1 (enExample)
ES (1) ES2792923T3 (enExample)
HK (2) HK1203478A1 (enExample)
IL (1) IL235446A0 (enExample)
MX (2) MX2014013341A (enExample)
PH (1) PH12014502449A1 (enExample)
SG (1) SG11201407162SA (enExample)
TW (1) TW201406707A (enExample)
WO (1) WO2013166449A2 (enExample)
ZA (1) ZA201408592B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112804999A (zh) * 2018-10-19 2021-05-14 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
CN112888440A (zh) * 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2541430C2 (ru) 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
US10471027B2 (en) * 2009-07-02 2019-11-12 Acucela, Inc. Pharmacology of visual cycle modulators
CN104703598A (zh) 2012-01-20 2015-06-10 奥克塞拉有限公司 用于疾病治疗的取代的杂环化合物
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
HK1219943A1 (zh) * 2013-03-12 2017-04-21 Acucela, Inc. 用於治疗眼科疾病和障害的取代3-苯基丙胺衍生物
JP6532854B2 (ja) * 2013-03-14 2019-06-19 オプティメディカ・コーポレイションＯｐｔｉｍｅｄｉｃａ Ｃｏｒｐｏｒａｔｉｏｎ レーザ水晶体嚢硝子体切開術
JP6692795B2 (ja) * 2014-04-10 2020-05-13 ランケナー インスティテュート フォー メディカル リサーチ 眼疾患および眼障害の治療のための方法および組成物
US10792374B2 (en) 2015-10-09 2020-10-06 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
AU2018223810B2 (en) * 2017-02-27 2022-04-21 Case Western Reserve University Visual cycle modulators
CN116807381A (zh) * 2017-12-28 2023-09-29 株式会社尼康 图像处理方法、图像处理程序、图像处理装置、图像显示装置、以及图像显示方法
MX2018008165A (es) * 2018-06-29 2019-12-30 Centro De Retina Medica Y Quirurgica S C Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial.
WO2020014074A1 (en) 2018-07-07 2020-01-16 Acucela Inc. Device to prevent retinal hypoxia
AU2019314262B2 (en) 2018-07-30 2025-04-03 Acucela Inc. An apparatus to treat myopia of an eye
US12256994B2 (en) * 2019-05-31 2025-03-25 Nikon Corporation Systems and methods for combining fundus images of an eye
JP2022542965A (ja) 2019-07-31 2022-10-07 アキュセラ インコーポレイテッド 画像を網膜上に投影するためのデバイス
EP4031933A4 (en) 2019-09-16 2023-10-11 Acucela Inc. METHOD FOR ASSEMBLY OF AN ELECTRONIC SOFT CONTACT LENS DESIGNED TO INHIBIT THE PROGRESSION OF MYOPIA
US11777340B2 (en) 2020-02-21 2023-10-03 Acucela Inc. Charging case for electronic contact lens
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
US11320674B2 (en) 2020-05-13 2022-05-03 Acucela Inc. Electro-switchable spectacles for myopia treatment
JP2023528301A (ja) 2020-06-08 2023-07-04 アキュセラ インコーポレイテッド 屈折異常を治療するための周辺網膜上への脱焦点化された画像の投影
JP2023528307A (ja) 2020-06-08 2023-07-04 アキュセラ インコーポレイテッド 周辺脱焦点化を使用して進行性屈折異常を治療するための貼付式デバイス
JP2023529875A (ja) 2020-06-08 2023-07-12 アキュセラ インコーポレイテッド 非点収差を治療するための非対称投影を伴うレンズ
US11281022B2 (en) 2020-06-10 2022-03-22 Acucela Inc. Apparatus and methods for the treatment of refractive error using active stimulation
US11209672B1 (en) 2021-04-06 2021-12-28 Acucela Inc. Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens
US11366341B1 (en) 2021-05-04 2022-06-21 Acucela Inc. Electronic case for electronic spectacles
AU2022278549A1 (en) * 2021-05-16 2023-12-07 Metanoia Bio Inc. Methods and compositions for treating ocular neovascular disease
WO2022255332A1 (ja) * 2021-06-03 2022-12-08 国立大学法人大阪大学 未熟児網膜症スクリーニング方法、スクリーニング装置及び学習済モデル
WO2024258981A2 (en) * 2023-06-12 2024-12-19 Synaptogenix, Inc. Methods for repairing nerve damage using pkc activating therapeutic agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101686665A (zh) * 2007-04-20 2010-03-31 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
US20110003895A1 (en) * 2009-07-02 2011-01-06 Acucela, Inc. Pharmacology of Visual Cycle Modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AP1750A (en) * 2001-11-09 2007-06-23 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
EP1727529B1 (en) * 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
NZ601866A (en) 2007-06-29 2013-12-20 Acucela Inc Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
RU2541430C2 (ru) * 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
MX2010004718A (es) 2007-11-01 2010-07-28 Acucela Inc Compuestos derivados de amina para tratar enfermedades y trastornos oftalmicos.
WO2010028088A2 (en) 2008-09-05 2010-03-11 Acucela, Inc. Sulfur-linked compounds for treating opthalmic diseases and disorders
EP2340242A4 (en) 2008-10-22 2012-04-04 Acucela Inc COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101686665A (zh) * 2007-04-20 2010-03-31 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
US20110003895A1 (en) * 2009-07-02 2011-01-06 Acucela, Inc. Pharmacology of Visual Cycle Modulators

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112888440A (zh) * 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途
CN112804999A (zh) * 2018-10-19 2021-05-14 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
CN112804999B (zh) * 2018-10-19 2024-03-15 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法

Also Published As

Publication number Publication date
US20180346407A1 (en) 2018-12-06
KR20150013240A (ko) 2015-02-04
CN107865830A (zh) 2018-04-03
EA201492031A1 (ru) 2015-05-29
ES2792923T3 (es) 2020-11-12
PH12014502449A1 (en) 2015-01-12
EP2844636A2 (en) 2015-03-11
US20210171435A1 (en) 2021-06-10
EP2844636B1 (en) 2020-04-22
TW201406707A (zh) 2014-02-16
JP2020023535A (ja) 2020-02-13
JP2023059991A (ja) 2023-04-27
JP2018024702A (ja) 2018-02-15
BR112014027571A2 (pt) 2017-07-18
CA2872433A1 (en) 2013-11-07
SG11201407162SA (en) 2014-11-27
HK1246646A1 (zh) 2018-09-14
US10730825B2 (en) 2020-08-04
CN116850163A (zh) 2023-10-10
US20140039048A1 (en) 2014-02-06
EP3741742A1 (en) 2020-11-25
EP2844636A4 (en) 2016-03-09
US20240308951A1 (en) 2024-09-19
US9957224B2 (en) 2018-05-01
WO2013166449A3 (en) 2014-01-30
ZA201408592B (en) 2017-09-27
MX2014013341A (es) 2015-06-02
JP2021075576A (ja) 2021-05-20
MX2020001835A (es) 2021-09-09
JP2025069362A (ja) 2025-04-30
IL235446A0 (en) 2014-12-31
WO2013166449A2 (en) 2013-11-07
MX386024B (es) 2025-03-18
HK1203478A1 (en) 2015-10-30
CA2872433C (en) 2022-06-28
AU2013256029A1 (en) 2014-12-04
BR112014027571B1 (pt) 2021-08-31
JP2015518491A (ja) 2015-07-02
US11795136B2 (en) 2023-10-24

Similar Documents

Publication Publication Date Title
US11795136B2 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
Kalouda et al. Achievements and limits of current medical therapy of glaucoma
JP2023509336A (ja) 過剰血管新生に関連する眼疾患を治療する化合物
CN110114066B (zh) 含沙丁胺醇的眼科药物
JP6908616B2 (ja) 網膜疾患の治療のためのミラベグロン
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
US20240342202A1 (en) Methods of Treating Retinal Vasculopathies
Mathebula A review of pharmacological therapy for glaucoma
HK40038867A (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
JP4412554B2 (ja) 網膜症のモデル動物
Sgambellone Histamine H3 receptor (H3R) antagonist-Nitric Oxide (NO) donor hybrid compounds as a new therapeutic strategy for the treatment of glaucoma and retinal neuroprotection
Ahmed Peribulbar injection of triamcinolone acetonide as an outpatient clinic procedure in the management of mild to moderate macular edema
Williamson et al. 14 Medical Therapy for Glaucoma
Dada et al. Medical Management of glaucoma
Mathebula Sports related traumatic hyphema
Kuriakose Management of Macular Edema Secondary to Branch Retinal Vein Occlusion with Intravitreal Bevacizumab and Macular Grid Laser
Attebo The medical therapies for chronic glaucoma
Ahmed et al. Comparison of the efficacy of diode laser cyclophotocoagulation alone or in conjunction with Avastin in the treatment of pseudovascular glaucoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203478

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150311

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1203478

Country of ref document: HK